{"id":809215,"date":"2025-02-05T09:22:09","date_gmt":"2025-02-05T14:22:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/"},"modified":"2025-02-05T09:22:09","modified_gmt":"2025-02-05T14:22:09","slug":"volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/","title":{"rendered":"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &#8220;Casting a New Light on Sepsis Management&#8221;, on February 14, 2025"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">HENDERSON, Nev.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 5, 2025<\/span><\/span> \/PRNewswire\/ &#8212; VolitionRx Limited (NYSE AMERICAN: VNRX) (&#8220;Volition&#8221;), a multi-national epigenetics company, today announced it will host a virtual investor event on <span class=\"xn-chron\">Friday, February 14, 2025<\/span> at <span class=\"xn-chron\">8:00 AM ET<\/span>, featuring Volition company management Dr. <span class=\"xn-person\">Andrew Retter<\/span>, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, <u><a href=\"https:\/\/lifescievents.com\/event\/volition\/\" target=\"_blank\" rel=\"nofollow\">click here.<\/a><\/u><\/p>\n<p>Dr. Retter will focus on Nu.Q\u00ae NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT).<u><a href=\"https:\/\/ir.volition.com\/news-events\/press-releases\/detail\/825\/large-clinical-study-establishes-nu-q-nets-h3-1-as-an-independent-predictor-of-28-day-mortality-in-sepsis\" target=\"_blank\" rel=\"nofollow\">\u00a0Recently published results from a large-scale study<\/a><\/u> indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis.<\/p>\n<p>Mr. Forterre will provide an update on Volition&#8217;s progress to commercialization through both licensing and direct and indirect sales.<\/p>\n<p>A live question and answer session will follow the formal presentations.<\/p>\n<p>\n        <b>About Dr. <span class=\"xn-person\">Andrew Retter<\/span><\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Andrew Retter, BSc<\/span> (Hons), MBBS, FRCP, FRCPath (Haem), DICM is Consultant in Critical Care, ECMO &amp; Thrombois and also the Clinical Lead for Critical Care at one of the UK&#8217;s largest hospitals in <span class=\"xn-location\">London<\/span>, where he has worked as a\u00a0 Consultant since 2014. He is also the Chief Medical Officer at Volition, a medical technology company that specializes in developing innovative diagnostic tools for cancer, sepsis and in particular immunothrombosis. Dr Retter has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals.<\/p>\n<p>\n        <b>About Gael Forterre<\/b>\n      <\/p>\n<p>Gael Forterre is the Chief Commercial Officer of Volition joining the team in 2021. He is focused on building a strong commercialization plan and team to drive the extensive range of products developed using the Nu.Q<sup>\u00ae<\/sup> platform. Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Pathify. He is currently the non-executive chairman of Vahau.<\/p>\n<p>Gael started his career as a hedge fund analyst in <span class=\"xn-location\">Paris<\/span> and worked in a number of investment banking and more recently executive roles for over fifteen plus years. Gael received a master&#8217;s in finance from Sorbonne Paris I and a double MBA from <span class=\"xn-org\">Columbia Business School<\/span> and the <span class=\"xn-org\">London Business School<\/span>.<\/p>\n<p>\n        <b>About Volition<\/b>\n      <\/p>\n<p>Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.<\/p>\n<p>Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also improve their quality of life.<\/p>\n<p>Volition&#8217;s research and development activities are centered in <span class=\"xn-location\">Belgium<\/span>, with an innovation laboratory and office in the U.S. and <span class=\"xn-location\">London<\/span>.<\/p>\n<p>The contents found at Volition&#8217;s website address are not incorporated by reference into this document and should not be considered part of this document.\u00a0 Such website address is included in this document as an inactive textual reference only.<\/p>\n<p>\n        <b>Media Enquiries:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Louise Batchelor<\/span>, Volition, <a href=\"mailto:mediarelations@volition.com\" target=\"_blank\" rel=\"nofollow\">mediarelations@volition.com<\/a> +44 (0)7557 774620<\/p>\n<p>\n        <b>Investor Relations:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Jeremy Feffer<\/span>, LifeSci Advisors, <a href=\"mailto:jfeffer@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">jfeffer@lifesciadvisors.com<\/a> +1-212-915-2568<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN12351&amp;sd=2025-02-05\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/volition-to-host-virtual-investor-event-on-nuq-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025-302368817.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/volition-to-host-virtual-investor-event-on-nuq-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025-302368817.html<\/a><\/p>\n<p>SOURCE  VolitionRx Limited<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN12351&amp;Transmission_Id=202502050915PR_NEWS_USPR_____LN12351&amp;DateId=20250205\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire HENDERSON, Nev. , Feb. 5, 2025 \/PRNewswire\/ &#8212; VolitionRx Limited (NYSE AMERICAN: VNRX) (&#8220;Volition&#8221;), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here. Dr. Retter will focus on Nu.Q\u00ae NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT).\u00a0Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis. Mr. Forterre will provide an update &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &#8220;Casting a New Light on Sepsis Management&#8221;, on February 14, 2025&#8243;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809215","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &quot;Casting a New Light on Sepsis Management&quot;, on February 14, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &quot;Casting a New Light on Sepsis Management&quot;, on February 14, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire HENDERSON, Nev. , Feb. 5, 2025 \/PRNewswire\/ &#8212; VolitionRx Limited (NYSE AMERICAN: VNRX) (&#8220;Volition&#8221;), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here. Dr. Retter will focus on Nu.Q\u00ae NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT).\u00a0Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis. Mr. Forterre will provide an update &hellip; Continue reading &quot;Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &#8220;Casting a New Light on Sepsis Management&#8221;, on February 14, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-05T14:22:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN12351&amp;sd=2025-02-05\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &#8220;Casting a New Light on Sepsis Management&#8221;, on February 14, 2025\",\"datePublished\":\"2025-02-05T14:22:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/\"},\"wordCount\":560,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN12351&amp;sd=2025-02-05\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/\",\"name\":\"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, \\\"Casting a New Light on Sepsis Management\\\", on February 14, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN12351&amp;sd=2025-02-05\",\"datePublished\":\"2025-02-05T14:22:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN12351&amp;sd=2025-02-05\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN12351&amp;sd=2025-02-05\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &#8220;Casting a New Light on Sepsis Management&#8221;, on February 14, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, \"Casting a New Light on Sepsis Management\", on February 14, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/","og_locale":"en_US","og_type":"article","og_title":"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, \"Casting a New Light on Sepsis Management\", on February 14, 2025 - Market Newsdesk","og_description":"PR Newswire HENDERSON, Nev. , Feb. 5, 2025 \/PRNewswire\/ &#8212; VolitionRx Limited (NYSE AMERICAN: VNRX) (&#8220;Volition&#8221;), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here. Dr. Retter will focus on Nu.Q\u00ae NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT).\u00a0Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis. Mr. Forterre will provide an update &hellip; Continue reading \"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &#8220;Casting a New Light on Sepsis Management&#8221;, on February 14, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-05T14:22:09+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN12351&amp;sd=2025-02-05","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &#8220;Casting a New Light on Sepsis Management&#8221;, on February 14, 2025","datePublished":"2025-02-05T14:22:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/"},"wordCount":560,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN12351&amp;sd=2025-02-05","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/","name":"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, \"Casting a New Light on Sepsis Management\", on February 14, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN12351&amp;sd=2025-02-05","datePublished":"2025-02-05T14:22:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN12351&amp;sd=2025-02-05","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN12351&amp;sd=2025-02-05"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/volition-to-host-virtual-investor-event-on-nu-q-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Volition to Host Virtual Investor Event on Nu.Q\u00ae NETs, &#8220;Casting a New Light on Sepsis Management&#8221;, on February 14, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809215"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809215\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}